Deerfield Management INSP Position
Exited4-Fund ConvergenceDeerfield Management exited their position in Inspire Medical Systems, Inc. (INSP) in Q3 2024, after holding the stock for 2 quarters.
The position was first reported in Q2 2024 and has been tracked across 2 quarterly 13F filings.
INSP is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout in 318 days (Feb 28, 2027), making the timing of Deerfield's position particularly relevant.
Short interest stands at 14.6% of float with 3.4 days to cover, indicating significant bearish positioning against the stock.
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Full company profile →Short Interest
14.6%
3.4 days to cover
Deerfield Management INSP Position History
Frequently Asked Questions
Does Deerfield Management own INSP?
No. Deerfield Management exited their position in Inspire Medical Systems, Inc. (INSP) in Q3 2024. They previously held the stock for 2 quarters.
How many hedge funds own INSP?
4 specialist biotech hedge funds currently hold INSP, including Driehaus Capital, Eventide Asset Management, Rock Springs Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy INSP?
Deerfield Management's position in INSP was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's INSP position increasing or decreasing?
Deerfield Management completely exited their INSP position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
INSPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →